logo
Politics and pediatric mental health don't mix

Politics and pediatric mental health don't mix

Fast Company25-06-2025
As a child and adolescent psychiatrist, I've spent the past two decades treating young people and working with families in crisis. And I can tell you this: The threats to youth mental health are bigger than we think, and they're not coming from where you might expect.
While the stigma around therapy and psychiatric care may be slowly receding, access to care is under siege. We're watching mental health supports erode at exactly the moment families need them most. And in the name of reform, new political efforts like the ' Make America Healthy Again' (MAHA) executive order are introducing even more barriers.
To be clear, we should absolutely be thoughtful about how we deliver care and prevent misuse of medication in kids' mental health treatment. But what we cannot do is politicize or pathologize the very tools that save lives.
A system in retreat
We are in the middle of a youth mental health crisis. According to the CDC, suicide was the second leading cause of death for youth ages 10 to 14 in 2023, the latest CDC data available. One in five children has a diagnosable mental health condition, yet almost two-thirds receive little to no treatment at all. And when care is delayed, the consequences can be severe: school dropout, addiction, chronic illness, even early death.
Yet, despite this, we're watching key supports disappear:
School-based mental health programs are being defunded. These programs often catch problems early and are sometimes the only care option for underserved kids.
Telehealth access is under threat, despite being a lifeline for rural families and working parents during the pandemic.
Medicaid redeterminations have put millions of children at risk of losing coverage.
Mental health medication access is being undermined by supply chain issues and growing skepticism around use, especially for conditions like ADHD.
MAHA's emphasis on 'over-utilization' of psychiatric medication only adds to the problem. When we focus on the wrong risks, we distract from the real ones: untreated illness, suffering families, and preventable tragedies.
Stigma with a new disguise
I'm seeing more and more skepticism about psychiatric treatment. Questions like, 'Are we overmedicating kids?' or 'Shouldn't we be building resilience instead?'
The thing is, it's not either-or. We treat diabetes with insulin and teach healthy habits. We manage asthma with inhalers and reduce environmental triggers. Mental health should be no different. Framing treatment as a failure, or something we should avoid unless we've tried everything else, only drives families deeper into shame. And for kids, that can translate into silence, hopelessness, and danger.
What kids and families actually need
We need a new model for mental health care—one that meets families where they are, uses the best available evidence, and doesn't leave them to figure it all out alone.
Here's what that looks like:
Integrated, team-based care. No one provider can do it all. Kids need therapists, psychiatric providers, and coaches who work together.
Early, proactive support. The longer we wait, the worse outcomes get. Let's reach kids early, way before they actually hit a crisis.
Technology that expands access, not replaces care. Telehealth and digital tools can help families overcome logistical barriers, especially when thoughtfully designed.
Respect for families. Parents shouldn't feel judged for seeking care. They should be met with empathy and real options.
Investment in workforce and innovation. We need to train more clinicians, pay them fairly, and support research into better treatments.
How can policymakers and leaders help?
So what can we actually do? First, we need to protect telehealth parity—because where a child lives shouldn't determine whether they can see a therapist. We need to fully fund school-based programs, so kids have access to care where they spend most of their time. And we have to stabilize Medicaid enrollment to prevent kids from falling through the cracks just because of paperwork.
We also must raise reimbursement rates for mental health care—because when providers burn out or leave the field, families are the ones left scrambling. Finally, we need to push back on stigma—especially in the way we write and talk about mental health in policy. This isn't the time for vague language or political posturing. It's time to be clear, evidence-based, and human.
Silence isn't neutral
It can feel risky to speak up. But as a clinician, a mom, and a human being, I can't stay quiet while kids fall through the cracks.
This isn't about left or right. It's about right and wrong. It's about whether we're willing to invest in our children's future or continue to make care harder to reach.
Mental health isn't a luxury. And every child deserves the chance to feel better. Let's stop building roadblocks and start building a future grounded in compassion, care, and real support.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories
BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories

Yahoo

time27 minutes ago

  • Yahoo

BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories

FRANKLIN LAKES, N.J., Aug. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC) and Surgery business units are the first in the medical technology industry to achieve a diamond-level rating for all seven supply chain resilience domains of the Healthcare Industry Resilience Collaborative's (HIRC) Resiliency Badging program. "Achieving HIRC's Diamond Status Resiliency Badge recognizes BD's commitment to building a resilient end-to-end supply chain across multiple product categories and our relentless pursuit of process excellence and continuous improvement," said Tony Ezell, executive vice president and president of the Americas region for BD. "Hundreds of millions of patients depend on BD, and this recognition is a testament to the work our team does every day to ensure products arrive on time and in the right quantities." HIRC is a non-profit health care supply chain trade association founded in 2019 by a group of health care systems and trading partners focused on increasing transparency and resiliency. The Resiliency Badge Program includes a rigorous audit to assess supply chain resiliency, ensuring alignment with HIRC's standards for supply continuity, risk mitigation and operational efficiency. After completing a comprehensive audit, HIRC recognized BD for differentiated resiliency in all domain areas for its Surgery and UCC businesses, including demand planning, supplier management, inventory management, logistics, supply chain visibility, risk management and continency planning, and operational health. BD was one of the first companies recognized by HIRC after receiving the Transparency Partner Badge in 2023. This diamond-level distinction builds on that recognition and demonstrates BD's ongoing investment in its supply chain and manufacturing operations, including increasing safety stock and capacity to allow greater flexibility for the most critical products and improving order management interfaces so customers have real-time insights into supply and deliveries. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series

Yahoo

time27 minutes ago

  • Yahoo

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series

WATERTOWN, Mass., August 05, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. "HCW@Home" series. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at or by registering here. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing Hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@

Garmin announces collaborations with leading brands for Garmin Marathon Series
Garmin announces collaborations with leading brands for Garmin Marathon Series

Yahoo

time27 minutes ago

  • Yahoo

Garmin announces collaborations with leading brands for Garmin Marathon Series

Companies will bring exciting activations to the expo, course and finish line festival OLATHE, Kan., Aug. 5, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Brooks, Dexcom, Maurten, Shokz and Therabody will support the Garmin Marathon Series with products and programming, beginning with the inaugural races in Toledo, Ohio on Sunday, Sept. 21. "As leaders in their respective fields, these brands are the ideal collaborators to enrich the signature experience we're creating for the Garmin Marathon Series. Each brings something unique to our events, whether they're engaging with runners at the two-day expo, providing support on the course or helping finishers recover and celebrate after the race."– Susan Lyman, Garmin Vice President of Consumer Sales and Marketing BrooksBrooks Running creates market-leading performance running footwear, apparel, sports bras, and accessories distributed worldwide, propelled since 1914 by a never-ending curiosity with how humans move, pushing the limits of motion science, engineering, and technology to create gear that unlocks the power of energy and movement for everyone. Each participant of the Garmin Marathon Series will receive a branded Brooks running shirt to commemorate the event. Additionally, Brooks will be onsite at the expo with its latest gear and along the course at a designated cheer station. DexcomDexcom empowers people to take control of health through innovative glucose biosensing technology. With Dexcom G7 and Stelo by Dexcom, its first over-the-counter glucose biosensor, it is easier than ever to get started with a biosensor that best suits each user's unique needs. Dexcom G7 and Stelo transform how runners track glucose levels and understand their metabolic health. Dexcom will have a presence at the expo and finish line festival, as well as a dedicated cheer zone along the course. MaurtenKnown for revolutionizing sports nutrition with its debut in 2015, Maurten has gained a reputation as the world's leading nutrition brand for endurance athletes. Runners will have access to Maurten gels at designated aid stations, empowering them to stay fueled and perform their best. Maurten will also be onsite at the expo. ShokzAs the pioneer and leader in open-ear listening, Shokz helps runners stay motivated, aware, and connected—without compromising on comfort or sound quality. Throughout the Garmin Marathon Series, Shokz will showcase its innovative headphones at the expo, power runners through the toughest miles with a high-energy cheer station, and join the celebration at the finish line festival. TherabodyBy supercharging performance with science-backed recovery devices, Therabody enables athletes to train harder, perform better and recover faster. Race participants can take advantage of an exclusive offer on Therabody recovery devices to support their training, and benefit from using them throughout race weekend in Therabody recovery zones at the expo, along the course and at the finish line festival. The Garmin Marathon Series is a bold new chapter in road running events, wholly owned and produced by Garmin, a global leader in fitness technology and pioneer of the first running smartwatch. Launching in fall 2025 with events in Toledo, Ohio, and Tucson, Arizona, the Series offers four race distances: a Boston Marathon qualifier full marathon, USATF-certified half marathon, 10K and 5K1. Registration for the Garmin Marathon Series is currently open for all race distances in Toledo and Tucson. For additional information about the cities, races, community engagement opportunities and future locations, please visit Engineered on the inside for life on the outside, Garmin products have revolutionized the aviation, automotive, fitness, marine and outdoor markets. Dedicated to helping people make the most of the time they spend pursuing their passions, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garmin on social, or follow our blog. 1Tucson courses are pending certification and subject to change. About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved. Notice on Forward-Looking Statements:This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 28, 2024, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983), and the Quarterly Report on Form 10-Q for the quarter ended June 28, 2025 filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). Copies of such Form 10-K and Form 10-Q are available at No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. MEDIA CONTACTS:Elliott View original content to download multimedia: SOURCE Garmin International, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store